Enzyvant Therapeutics
Enzyvant Therapeutics works on 1 rare disease tracked on Trial Friend, including Congenital Athymia, with 1 FDA-approved rare disease drug.
Enzyvant, a subsidiary of Sumitomo Pharma, develops regenerative medicine therapies for rare pediatric immune system disorders. The company's FDA-approved RETHYMIC is a groundbreaking therapy that implants processed thymus tissue to rebuild immune function in children with congenital athymia.
Focus areas at Enzyvant Therapeutics
As a rare disease specialist, Enzyvant Therapeutics has active clinical trial programs and drug development efforts across 1 rare diseases, including Congenital Athymia. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Enzyvant Therapeutics, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Enzyvant Therapeutics is headquartered in Cary, United States, founded in 2016, a subsidiary of Sumitomo Pharma. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Enzyvant Therapeutics. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Congenital Athymia. Turn any of these off from the link in every email.
Enzyvant Therapeutics FDA-Approved Drugs (1)
Medications developed or marketed by Enzyvant Therapeutics that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| ALLOGENEIC PROCESSED THYMUS TISSUE-AGDC | RETHYMIC | — |
Rare Disease Focus Areas (1)
Diseases targeted by Enzyvant Therapeutics's clinical trial and drug development programs
Patient Resources
Organizations and resources related to Enzyvant Therapeutics's rare disease focus areas
Frequently Asked Questions About Enzyvant Therapeutics
Common questions about Enzyvant Therapeutics's rare disease programs, clinical trials, and treatments.